Lenvatinib And Stereotactic radiothErapy With pembRolizumab in Metastatic Kidney Cancer Patients
A Randomized Phase 2 Trial of Lenvatinib Plus Pembrolizumab With or Without Stereotactic Radiation Therapy in Patients With Clear-cell Metastatic Renal Cell Carcinoma, Low Tumor Burden, and Stable Disease.
Metastatic clear-cell renal cell carcinoma (ccRCC) is sensitive to therapy with lenvatinib and pembrolizumab. The CLEAR trial demonstrated positive outcomes even in patients with a low tumor burden. In a subset of patients with metastatic ccRCC, the presence of a low tumor burden suggests that incorporating stereotactic body radiotherapy (SBRT) into systemic therapy could be a strategy to enhance the anti-tumor response, while maintaining an acceptable toxicity profile. This study evaluates the contribution of SBRT in a subgroup of patients who have achieved stable disease while receiving lenvatinib and pembrolizumab.
調査の概要
状態
詳細な説明
Metastatic clear cell renal cell carcinoma (mRCC) is sensitive to combination of lenvatinib and pembrolizumab. The CLEAR study showed positive results in patients with low tumor burden. However, around 20% of patients do not respond and have stable disease. In the VOLGA study, we demonstrated better outcomes in patients with irradiation of even a single lesion during targeted therapy. Thus, investigators hypothesize that stereotactic radiotherapy (SBRT) to multiple lesions in patients undergoing ongoing therapy with pembrolizumab and lenvatinib will increase the objective response rate, which may correlate with improved overall survival.
LASER is a randomized multicenter phase 2 study. Initially, all patients with histologically confirmed mRCC, the median sum of the diameters of target lesions ≥ 7 cm, ECOG 0-2, and the absence of prior systemic therapy for metastatic disease will receive a 12-week induction with lenvatinib and pembrolizumab, followed by radiological assessment according to RECIST 1.1 and allocation by outcome (response, stable disease, or disease progression). Patients with stable disease (SD) will be randomized in a 1:1 ratio into two groups: 1) lenvatinib + pembrolizumab + SBRT (N=27) or 2) lenvatinib + pembrolizumab alone (N=27). In the SBRT group, the choice of target for irradiation - up to 3 (three) lesions - is determined by a multidisciplinary team. The primary endpoint is the objective response rate (ORR) of unirradiated lesions after randomization among patients with stable disease (assessed every 12 weeks according to RECIST 1.1). The statistical hypothesis is based on an expected ORR of 15% in the control group versus 50% in the SBRT group. A two-sided α of 0.05 and a power of 80% require 27 patients in each group (54 randomized). The total enrollment will be 150 patients.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Ilya Tsimafeyeu
- 電話番号:+74999054690
- メール:sten_to@mail.ru
研究場所
-
-
-
Kazan'、ロシア、420000
- 募集
- Republican Dispensary of Tatarstan
-
コンタクト:
- Milyausha Mukhitova
- 電話番号:+74999054690
- メール:sten_to@mail.ru
-
Moscow、ロシア、115478
- 募集
- N.N. Blokhin National Medical Research Center of Oncology
-
コンタクト:
- Petr Bulychkin
- 電話番号:+74999054690
- メール:sten_to@mail.ru
-
Moscow、ロシア、125630
- 募集
- STOONCO clinic
-
コンタクト:
- Valentina Leonenko
- 電話番号:+7 (915) 809-03-03
- メール:bucare@bucare.org
-
Orenburg、ロシア、460000
- 募集
- Orenburg Regional Cancer Center
-
コンタクト:
- Makhabbat Murzalina
- 電話番号:+74999054690
- メール:sten_to@mail.ru
-
Saint Petersburg、ロシア、194291
- 募集
- SBHI Leningrad Regional Clinical Hospital
-
コンタクト:
- Andrey Lebedinets
- 電話番号:+74999054690
- メール:sten_to@mail.ru
-
Tyumen、ロシア、625000
- 募集
- Cancer Center "Medical City"
-
コンタクト:
- Vera Peryshkina
- 電話番号:+74999054690
- メール:sten_to@mail.ru
-
Ufa、ロシア、450000
- 募集
- Republican Clinical Oncology Dispensary
-
コンタクト:
- Alexander Sultanbaev
- 電話番号:+7 (347) 216-3671
- メール:ufa.rkod@doctorrb.ru
-
Ulyanovsk、ロシア、432000
- 募集
- "ErSpace" Radiation Therapy Center
-
コンタクト:
- Natalia Dengina
- 電話番号:+78422737472
- メール:info@rspei.ru
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age ≥ 18 years.
- Histologically confirmed clear-cell renal cell carcinoma.
- Presence of measurable lesions per RECIST 1.1.
- Sum of diameters of target lesions ≤ 7 cm.
- ECOG 0-2.
- No prior systemic therapy for metastatic disease.
Exclusion Criteria:
- Uncontrolled comorbidities that preclude the use of TKI/IO or SBRT.
- Prior SBRT to the lesions planned for irradiation, rendering re-irradiation unsafe.
- Active autoimmune diseases requiring systemic immunosuppressants.
- Symptomatic CNS metastases (patients with asymptomatic metastases may be included).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Lenvatinib + Pembrolizumab + SBRT
|
20 mg orally once daily. 200 mg intravenously every 3 weeks The dosage regimen is determined by a radiation oncologist and depends on the location of the lesion. |
|
アクティブコンパレータ:Lenvatinib + Pembrolizumab
|
20 mg orally once daily. 200 mg intravenously every 3 weeks |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants with Response of unirradiated lesions according to RECIST v1.1
時間枠:Percentage of patients with response at week 12
|
Objective response rate (ORR) of unirradiated lesions after randomization among patients with stable disease |
Percentage of patients with response at week 12
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Median progression-free survival
時間枠:From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months.
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months.
|
|
Median overall survival
時間枠:From date of randomization until the date of death from any cause, whichever came first, assessed up to 60 months.
|
From date of randomization until the date of death from any cause, whichever came first, assessed up to 60 months.
|
|
Median duration of response
時間枠:From the first response to the date of disease progression or death for any reason, whichever came first, assessed up to 36 months.
|
From the first response to the date of disease progression or death for any reason, whichever came first, assessed up to 36 months.
|
|
Rate of local control of irradiated lesions
時間枠:Percentage of stable irradiated lesions at week 12
|
Percentage of stable irradiated lesions at week 12
|
|
Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0
時間枠:Rate of treatment-related adverse events at week 24
|
Rate of treatment-related adverse events at week 24
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Ilya Tsimafeyeu et al. A randomized phase 2 trial of lenvatinib plus pembrolizumab with or without stereotactic body radiotherapy in patients with metastatic renal cell carcinoma, low tumor burden, and stable disease (LASER).. J Clin Oncol 44, TPS583-TPS583(2026). DOI:10.1200/JCO.2026.44.7_suppl.TPS583
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- LASER
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
In accordance with local legislation
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。